Medscape www.medscape.com

References for:
Treatment of Mitochondrial Cytopathies

[Semin Neurol 21(3):309-325, 2001. © 2001 Thieme Medical Publishers]

  1. Chinnery PF, Howell N, Lightowlers RN, Turnbull DM. Molecular pathology of MELAS and MERRF: the relationship between mutation load and clinical phenotypes. Brain 1997; 120:1713-1721
  2. Lauwers MH, Van Lersberghe C, Camu F. Inhalation anaesthesia and the Kearns-Sayre syndrome. Anaesthesia 1994;49: 876-878
  3. Burns AM, Shelly MP. Anaesthesia for patients with mitochondrial myopathy. Anaesthesia 1989;44:975-977
  4. D'Ambra MN, Dedrick D, Savarese JJ. Kearns-Sayre syndrome and pancuronium-succinylcholine-induced neuromuscular blockade. Anesthesiology 1979;51:343-345
  5. Casta A, Quackenbush EJ, Houck CS, et al. Perioperative white matter degeneration and death in a patient with a defect in mitochondrial oxidative phosphorylation. Anesthesiology 1997;87:420-425
  6. Kitoh T, Mizuno K, Otagiri T, Ichinose A, Sasao J, Goto H. Anesthetic management for a patient with Kearns-Sayre syndrome. Anesth Analg 1995;80:1240-1242
  7. Barohn RJ, Clanton T, Sahenk Z, Mendell JR. Recurrent respiratory insufficiency and depressed ventilatory drive complicating mitochondrial myopathies. Neurology 1990;40:103- 106
  8. Maslow A, Lisbon A. Anesthetic considerations in patients with mitochondrial dysfunction. Anesth Analg 1993;76: 884-886
  9. Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectant spectroscopy. Crit Care Med 2000;28: 172-177
  10. Przyrembel H. Therapy of mitochondrial diseases. J Inherit Metab Dis 1987;10(suppl 1):129-146
  11. Taivassalo T, De Stefano N, Argov Z, et al. Effects of aerobic training in patients with mitochondrial myopathies. Neurology 1998;50:1055-1060
  12. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. Pharmacokinetics, metabolism, and toxicology of dichloroacetate. Drug Metab Rev 1998;30:499-539
  13. Stacpoole PW, Barnes CL, Hurbanis MD, Cannon SL, Kerr DS. Treatment of congenital lactic acidosis with dichloroacetate. Arch Dis Child 1997;77:535-541
  14. Stacpoole PW, Lorenz AC, Thomas RG, Harman EM. Dichloroacetate in the treatment of lactic acidosis. Ann Inter Med 1988;108:58-63
  15. Stacpoole PW, Wright EC, Baumgartner TG, et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med 1992;327:1564-1569
  16. Kuroda Y, Ito M, Naito E, et al. Concomitant administration of sodium dichloroacetate and vitamin B1 for lactic acidemia in children with MELAS syndrome. J Pediatr 1997;131: 450-452
  17. Saijo T, Naito E, Ito M, Takeda E, Hashimoto T, Kuroda Y. Therapeutic effect of sodium dichloroacetate on visual and auditory hallucinations in a patient with MELAS. Neuropediatrics 1991;22:166-167
  18. Kimura S, Osaka H, Saitou K, Ohtuki N, Kobayashi, Nezu A. Improvement of lesions shown on MRI and CT scan by administration of dichloroacetate in patients with Leigh syndrome. J Neurol Sci 1995;134:103-107
  19. Tulinius MH, Eriksson BO, Hjalmarson O, Holme E, Oldfors A. Mitochondrial myopathy and cardiomyopathy in siblings. Pediatr Neurol 1989;5:182-188
  20. Takanashi J, Sugita K, Tanabe Y, Maemoto T, Niimi H. Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation. J Neurol Sci 1997;145:83- 86
  21. DeStefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology 1995;45:1193-1198
  22. Pavlakis SG, Kingsley PB, Kaplan GP, Stacpoole PW, O'Shea M, Lustbader D. Magnetic resonance spectroscopy: use in monitoring MELAS treatment. Arch Neurol 1998;55: 849-852
  23. Kimura S, Ohtuki N, Nezu A, Tanaka M, Takeshita S. Clinical and radiologic improvements in mitochondrial encephalomyopathy following sodium dichloroacetate therapy. Brain Dev 1997;19:535-540
  24. Ogasahara S, Engel A, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A 1989;86:2379-2382
  25. Goda S, Hamada T, Ishimoto S, Kobayashi T, Goto I, Kuroiwa Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J Neurol 1987;234:62-63
  26. Ogasahara S, Yorifuji S, Nishikawa Y, et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Q10 in Kearns-Sayre syndrome. Neurology 1985;35:372-377
  27. Bresolin N, Bet L, Binda A, et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology 1988;38:892-899
  28. Abe K, Fujimura H, Nishikawa Y, et al. Marked reduction in CSF lactate and pyruvate levels after CoQ therapy in a patient with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). Acta Neurol Scand 1991;83:356-359
  29. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies: short-term double-blind, crossover study. Eur Neurol 1997;37:212-218
  30. Chan A, Reichmann H, Koegel A, Beck A, Gold R. Metabolic changes in patients with mitochondrial myopathies and effects of coenzyme Q10 therapy. J Neurol 1998;245:681-685
  31. Bresolin N, Doriguzzi C, Ponzetto C, et al. Ubidecarenone in the treatment of mitochondrial myopathies: a multi-center double-blind trial. J Neurol Sci 1990;100:70-78
  32. Zierz S, von Wersebe O, Bleistein J, Jerusalem F. Exogenous coenzyme Q (CoQ) fails to increase CoQ in skeletal muscle of two patients with mitochondrial myopathies. J Neurol Sci 1990;95:283-290
  33. Matthews PM, Ford B, Dandurand RJ, et al. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 1993;43:884-890
  34. Eleff SM, Barker PB, Blackband SJ, et al. Phosphorous magnetic resonance spectroscopy of patients with mitochondrial cytopathies demonstrates decreased levels of brain phosphocreatine. Ann Neurol 1990;27:626-630
  35. Argov Z, Bank WJ. Phosphorous magnetic resonance spectroscopy (31P MRS) in neuromuscular disorders. Ann Neurol 1991;30:90-92
  36. Gold R, Seibel P, Reinelt G, et al. Phosphorous magnetic resonance spectroscopy in the evaluation of mitochondrial myopathies: results of a 6-month therapy study with coenzyme Q. Eur Neurol 1996;36:191-196
  37. Barbiroli B, Iotti S, Lodi R. Improved brain and muscle mitochondrial respiration with CoQ: an in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. BioFactors 1999;9:253-260
  38. Bendahan D, Desnuelle C, Vanuxen D, et al. 31P NMR spectroscopy and ergometer exercise test as evidence for muscle oxidative performance improvement with coenzyme Q in mitochondrial myopathies. Neurology 1992;42:1203-1209
  39. Cortelli P, Montagna P, Pierangeli G, et al. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study. J Neurol Sci 1997;148:25-31
  40. Mashima Y, Hiida Y, Oguchi Y. Remission of Leber's hereditary optic neuropathy with idebenone. Lancet 1992;340:368-369
  41. Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J Neurol Sci 1989;90:263-271
  42. Schmidt-Sommerfield E, Werner D, Penn D. Carnitine plasma concentrations in 353 metabolically healthy children. Eur J Pediatr 1988;147:356-360
  43. Angelini C, Vergani L, Martinuzzi A. Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation. Crit Rev Clin Lab Sci 1992;29:217-242
  44. Pons R, DeVivo DC. Primary and secondary carnitine deficiency syndromes. J Child Neurology 1995;10(suppl 2):9-24
  45. Carter AL, Abney TO, Lapp DF. Biosynthesis and metabolism of carnitine. J Child Neurol 1995;10(suppl 2):3-7
  46. Bellei M, Battelli D, Guarriero DM, et al. Changes in mitochondrial activity caused by ammonium salts and the protective effect of carnitine. Biochem Biophys Res Commun 1989; 158:181-188
  47. Campos Y, Huertas R, Lorenzo G, et al. Plasma carnitine insufficiency and effectiveness of L-carnitine therapy in patients with mitochondrial myopathy. Muscle Nerve 1993;16:150-153
  48. Harris RC, Soderlund K, Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin Sci 1992;83:367-374
  49. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20:1502-1509
  50. Tarnopolsky MA, Martin J. Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology 1999;52:854-857
  51. Odland LM, MacDougall JD, Tarnopolsky MA, Elorriaga A, Borgmann A. The effect of oral Cr supplementation on muscle [PCr] and short-term maximal power output. Med Sci Sports Exerc 1997;29:216-219
  52. Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu(UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42:2147-2152
  53. Griebel V, Kraegeloh-Mann I, Ruitenbeek W, Trijbels JMF, Paulus W. A mitochondrial myopathy in an infant with lactic acidosis. Dev Med Child Neurol 1990;32:528-531
  54. Bernsen PLJA, Gabreels FJM, Ruitenbeek W, Hamburger HL. Treatment of complex I deficiency with riboflavin. J Neurol Sci 1993;118:181-187
  55. Arts WFM, Scholte HR, Bogaard JM, Kerrebijn KF, Luyt-Houwen IEM. NADH-CoQ reductase deficient myopathy: successful treatment with riboflavin. Lancet 1983;2:581-582
  56. Bernsen PLJA, Gabreels FJM, Ruitenbeek W, Sengers RCA, Stadhouders AM, Renier WO. Successful treatment of pure myopathy, associated with complex I deficiency, with riboflavin and carnitine. Arch Neurol 1991;48:334-338
  57. Ogle RF, Christodoulou J, Fagan E, et al. Mitochondrial myopathy with tRNALeu(URR) mutation and complex I deficiency responsive to riboflavin. J Pediatr 1997;130:138-145
  58. Hoppel CL, Kerr DS, Dahms B, Roessmann U. Deficiency of the reduced nicotinamide adenine dinucleotide dehydrogenase component of complex I of mitochondrial electron transport. J Clin Invest 1987;80:71-77
  59. Ichiki T, Tanaka M, Nishikimi M, et al. Deficiency of subunits of complex I and mitochondrial encephalomyopathy. Ann Neurol 1988;23:287-294
  60. Lou HC. Correction of increased plasma pyruvate and plasma lactate levels using large doses of thiamine in patients with Kearns-Sayre syndrome. Arch Neurol 1981;38:469
  61. Mastaglia FL, Thompson PL, Papadimitriou JM. Mitochondrial myopathy with cardiomyopathy, lactic acidosis: response to prednisone and thiamine. Aust N Z J Med 1980;10: 660-664
  62. Cooper JM, Hayes DJ, Challiss RAJ, Morgan-Hughes JA, Clark JB. Treatment of experimental NADH ubiquinone reductase deficiency with menadione. Brain 1992;115: 991-1000
  63. Eleff S, Kennaway NG, Buist NRM, et al. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci U S A 1984;81:3529-3533
  64. Argov Z, Bank WJ, Maris J, et al. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: a 31P-NMR follow-up study. Ann Neurol 1986;19: 598-602
  65. Toscano A, Fazio MC, Vita G, et al. Early-onset cerebellar ataxia, myoclonus and hypogonadism in a case of mitochondrial complex III deficiency treated with vitamins K3 and C. J Neurol 1995;242:203-209
  66. Allen RJ, DiMauro S, Coulter DC, Papadimitriou A, Rothenberg SP. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol 1983;13:679-682
  67. Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochimica Biophysica Acta 1995; 1271:275-280
  68. Artuch R, Vilaseca MA, Pineda M. Biochemical monitoring of the treatment in paediatric patients with mitochondrial disease. J Inherit Metab Dis 1998;21:837-845
  69. Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol 1995;242:472-477